Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive ...
Benzinga.com

FDA Grants Fast Track Review To Johnson & Johnson's Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva

The U.S. Food and Drug Administration granted on Tuesday Fast Track designation to Johnson & Johnson’s (NYSE:JNJ) investigational nipocalimab for moderate-to-severe Sjögren’s disease (SjD). Last year, ...
Seeking Alpha

Johnson & Johnson to resume U.S. Varipulse cases after safety review

Johnson & Johnson (NYSE:JNJ) has decided to resume a limited market rollout of its heart rhythm device Varipulse after an investigation indicated no safety concerns, the MedTech giant announced.
Seeking Alpha

J&J gets FDA priority review for drug releasing system for bladder cancer

Johnson & Johnson (NYSE:JNJ) announced on Thursday that the U.S. FDA granted priority review for its new drug application aimed at getting marketing approval for TAR-200, a drug-releasing system for ...